Chemotherapy after surgery for aggressive prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether adding chemotherapy after standard treatment helps people with a very aggressive type of prostate cancer (Gleason score 9-10). It is designed for those who have not had their cancer spread to distant parts of the body and are healthy enough to handle chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your prostate cancer must be high-grade (Gleason score 9 or 10) based on a biopsy or surgery report.
- You cannot have cancer that has spread to distant organs or bones (confirmed by scans).
- You must be planning to have either surgery to remove the prostate or radiation therapy, or have already had these treatments.
- You should be in generally good health, with a performance status that allows you to do most of your daily activities without help (KPS 80 or higher).
- Your blood cell counts must be high enough: white cells and neutrophils (infection fighters) above certain levels, and platelets (clotting cells) also above a minimum level.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether removing the prostate (surgery) plus standard hormone therapy and chemotherapy can help men whose prostate cancer has spread to many places in the body. It is for men who have not yet had treatment for their cancer.
This trial looks at radiation therapy given after prostate surgery (or if needed later) for prostate cancer where lymph nodes were not involved. It may help patients whose PSA rises or who need additional treatment to reduce the chance the cancer comes back.
This trial tests a new combination of drugs given before surgery for locally advanced prostate cancer. The goal is to see if giving these drugs first helps shrink the tumor and improves outcomes after surgery.
This study tests a combination of three drugs—ADI-PEG20, carboplatin, and cabazitaxel—in men with aggressive variant prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination can shrink or slow the cancer.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This trial compares different chemotherapy drugs given around the time of surgery to see which approach works best for men with certain locally advanced prostate cancer. It may help find a better way to control the cancer after surgery.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.